Identifying gaps in the treatment of hepatitis C in patients co-infected with HIV in Edmonton, Alberta.
暂无分享,去创建一个
[1] Richard D Moore,et al. Hepatitis C Elimination in People With HIV Is Contingent on Closing Gaps in the HIV Continuum , 2019, Open forum infectious diseases.
[2] Z. Butt,et al. The population level care cascade for hepatitis C in British Columbia, Canada as of 2018: Impact of direct acting antivirals , 2019, Liver international : official journal of the International Association for the Study of the Liver.
[3] C. Coffin,et al. Achievement of hepatitis C cascade of care milestones: a population-level analysis in Alberta, Canada , 2019, Canadian Journal of Public Health.
[4] M. Mugavero,et al. Hepatitis C Virus Elimination in the Human Immunodeficiency Virus-Coinfected Population: Leveraging the Existing Human Immunodeficiency Virus Infrastructure. , 2018, Infectious disease clinics of North America.
[5] M. Hellard,et al. Linkage and retention in HCV care for HIV‐infected populations: early data from the DAA era , 2018, Journal of the International AIDS Society.
[6] J. V. D. van der Meer,et al. Spontaneous Clearance of Hepatitis C Virus Infection Among Human Immunodeficiency Virus–Infected Men Who Have Sex With Men , 2017, Open forum infectious diseases.
[7] Z. Butt,et al. The Population Level Cascade of Care for Hepatitis C in British Columbia, Canada: The BC Hepatitis Testers Cohort (BC-HTC) , 2016, EBioMedicine.
[8] Lisa P. Barrett,et al. CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core Research Group: 2016 Updated Canadian HIV/Hepatitis C Adult Guidelines for Management and Treatment , 2016, The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale.
[9] P. Easterbrook,et al. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. , 2016, The Lancet. Infectious diseases.
[10] M. Gill,et al. Treatment outcomes with telaprevir-based therapy for HIV/hepatitis C coinfected patients are comparable with hepatitis C monoinfected patients , 2015, The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale.
[11] D. Dieterich,et al. Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1. , 2015, The New England journal of medicine.
[12] E. Moodie,et al. Changes in quality of life, healthcare use, and substance use in HIV/hepatitis C coinfected patients after hepatitis C therapy: a prospective cohort study , 2015, HIV clinical trials.
[13] Terry Lee,et al. Rate, delay and predictors of hepatitis C treatment in British Columbia. , 2015, Canadian journal of gastroenterology & hepatology.
[14] T. Pilot‐Matias,et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. , 2015, JAMA.
[15] J. Rockstroh,et al. Managing HIV/hepatitis C co-infection in the era of direct acting antivirals , 2013, BMC Medicine.
[16] T. Hoffmann,et al. Cost effectiveness of patient education for the prevention of falls in hospital: economic evaluation from a randomized controlled trial , 2013, BMC Medicine.
[17] J. Kaldor,et al. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies , 2006, Journal of viral hepatitis.
[18] T. Heeren,et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.